TNO and FAST (Financiering en Acceleratie voor Therapieontwikkeling) have launched a strategic collaboration to accelerate the development of advanced therapies, including ATMPs, radiopharmaceuticals, treatments for rare diseases, infectious diseases, and drug repurposing.
Highlights:
Shared ambition to accelerate drug discovery by leveraging TNO’s innovation capabilities and deep collaborations with industry, government, and society.
Conny Helder (former Minister of Health) appointed as FAST’s new board chair, bringing strong leadership and signalling a strengthened link with TNO in publicly funded therapy programmes.
This partnership combines TNO’s technical and operational strength with FAST’s independent expert role, aiming to scale innovations that are both effective and affordable for patients.
Read more here
Researchers at Leiden University Medical Center (LUMC) have mapped the mechanism of action of a promising new antibiotic. Under a cryo-electron microscope, researchers Mia Urem...
Leiden, November 12 - The project “Omics in the Polder” from Leiden University of Applied Sciences has been nominated for the RAAK Award. This award is presented annually to the...
Leiden Bio Science Park welcomes Eli Lilly, strengthening The Netherlands' position in life sciences with a $3 billion facility. Eli Lilly and Company announced plans to build a...